PDB25 COST-EFFECTIVENES OF REAL-WORLD USE OF GLP-1 RECEPTOR AGONISTS VERSUS OTHER GLUCOSE-LOWERING AGENTS IN TYPE 2 DIABETES
May 1, 2020, 00:00
10.1016/j.jval.2020.04.213
https://www.valueinhealthjournal.com/article/S1098-3015(20)30401-0/fulltext
Title :
PDB25 COST-EFFECTIVENES OF REAL-WORLD USE OF GLP-1 RECEPTOR AGONISTS VERSUS OTHER GLUCOSE-LOWERING AGENTS IN TYPE 2 DIABETES
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)30401-0&doi=10.1016/j.jval.2020.04.213
First page :
Section Title :
Open access? :
No
Section Order :
10071